Chin et al reported that prior exposure to platinum agents could affect the subsequent response to erlotinib in a cell culture model of an erlotinib-sensitive EGFR-mutant NSCLC cell line [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.